CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vaso Active Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vaso Active Pharmaceuticals, Inc.
99 Rosewood Drive
Suite 260
Phone: (978) 750-0090p:978 750-0090 Danvers, MA  01923  United States Ticker: VAPHQVAPHQ
Filed for Bankruptcy on 3/11/2010
This company ceased filing statements with the SEC on 3/31/2009.
Case #10-10855, filed in the U.S. Bankruptcy Court for the District of Delaware
This company is no longer actively traded on any major stock exchange.
Business Summary
Vaso Active Pharmaceuticals, Inc. is a company focused on commercializing, marketing and selling over-the-counter (OTC) pharmaceutical products. Vaso Active Pharmaceuticals owns the exclusive OTC worldwide license to use and practice a patented vaso active lipid encapsulated (VALE) technology. The technology uses an active process incorporating chemical vasodilators to deliver drugs through the skin and into the bloodstream. PENtoCORE technology is a topical formulation, in contrast to the VALE transdermal technology. Vaso Active Pharmaceuticals is marketing three products that incorporate the PENtoCORE technology: OSTEON, A-R EXTREME and TERMIN8. OSTEON is a OTC external analgesic designed to provide temporary relief from the muscular-skeletal pain associated with arthritis. A-R EXTREME is an OTC external analgesic designed to provide temporary relief from the muscle and joint pain associated with athletic activity. TERMIN8 is an OTC antifungal lotion designed to treat athlete's foot.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200812/31/2007YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Robert E.Anderson 52 9/17/2004 6/1/2003
President, Acting Chief Executive Officer, Chief Financial Officer JosephFrattaroli 45 2/1/2005 6/1/2003
Vice President, Chief Scientific Officer, Director Stephen G.Carter 55 6/1/2003
4 additional Officers and Directors records available in full report.

Business Names
Business Name
VAPHQ
Vaso Active Pharmaceuticals, Inc.

General Information
Number of Employees: 9 (As of 3/31/2008)
Outstanding Shares: 10,328,604 (As of 11/11/2008)
Shareholders: 28
Stock Exchange: OTC
Federal Tax Id: 020670926
Fax Number: (978) 750-0085


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023